Sanofi, drugmaker behind Zantac, has agreed to settle 4,000 lawsuits The suits claim that discontinued Zantac contained cancer-causing chemicals READ MORE: Has heartburn pill that has been given ...

So why would GSK, the largest of the four major distributors of the now-recalled stomach acid drug, suddenly abandon the tried-and-true defense mantra, “millions for defense, not a penny for tribute”?

The first lawsuit claiming that gastrointestinal drug Zantac causes cancer has been voluntarily dismissed a week before it was due to come to trial, in an early victory for the pharma companies ...

(Bloomberg) -- Pfizer Inc. has agreed to settle more than 10,000 cases accusing it of hiding the cancer risks of its Zantac ...

GSK has opted to settle a key lawsuit in its defence against claims that its Zantac drug caused cancer, rather than proceed with a jury trial. The company said this morning it had reached a ...

GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.

Nevertheless, personal injury cases are beginning to trickle in, with the plaintiffs claiming that, like Zantac: “The U.S. Food and Drug Administration (FDA) recalled the blood pressure medication ...

has announced that it has agreed to settle nearly 80,000 state-level Zantac cases. The lawsuits claimed that the now-discontinued version of the heartburn drug caused cancer, although GSK says ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug. GSK suffered ...

GSK launched Zantac in 1981 and it was first approved for sale in the US in 1983 as a prescription medication. It went on to become the world's best-selling drug, with annual sales in excess of $1bn.

Get detailed information on Ranitidine, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

16 clinical studies showing no link between Zantac and cancer; the US Food and Drug Administration clearing Zantac to reenter the market; and recent litigation wins by GSK, including a case in ...